Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Adaptimmune Therapeutics (473A) AI Stock Analysis

0 Followers
DE:473A

Adaptimmune Therapeutics

(Munich:473A)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Gross Margin StrengthA 98% TTM gross margin suggests the SPEAR T‑cell platform can capture significant value per unit of revenue and offers high structural operating leverage. If clinical programs and partnerships scale, high gross margins support durable profitability expansion once fixed R&D costs are amortized.
Negative Factors
Steep Revenue DeclineA ~64% TTM revenue drop indicates material setbacks or lumpy partner payments that weaken revenue predictability. Persistent top‑line decline undermines ability to scale fixed investments, erodes bargaining leverage in partnerships, and constrains the timeline for converting high gross margins into sustainable operating profits.

Adaptimmune Therapeutics (473A) vs. iShares MSCI Germany ETF (EWG)

-75%-50%-25%0%25%50%75%DE:473A-62.50%EWG+6.38%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 7.95M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.1
Beta (1Y)
-0.09
Revenue Growth
―
EPS Growth
―
Country
Germany
Employees
272
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Adaptimmune Therapeutics Business Overview & Revenue Model

Company Description

Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as...

Adaptimmune Therapeutics Earnings Call Summary

Earnings Call Date:May 13, 2025(Q1-2025)|% Change Since:-94.64%|Next Earnings Date:Nov 05, 2025
Earnings Call SentimentPositive

Adaptimmune reported a very successful launch of TECELRA with strong initial sales and effective patient access. The early activation of treatment centers and manufacturing success further support their positive outlook. However, financial challenges remain with doubts about their ability to continue as a going concern.

Positive Updates

Strong TECELRA Launch with Revenue Guidance
Adaptimmune reported a successful launch of TECELRA with 21 patients apheresed in 2025, 13 in Q1 and 8 in early Q2. They provided revenue guidance for the full year of $35 million to $45 million in TECELRA sales.

Negative Updates

Substantial Doubt About Going Concern
The company reported substantial doubt about its ability to continue as a going concern, indicating less than 12 months of cash available and uncertainty in cash runway guidance.

Company Guidance

In the first quarter of 2025, Adaptimmune reported significant progress in the launch of TECELRA, with 21 patients apheresed to date, including 13 in Q1 and 8 in early Q2. The company provided revenue guidance for the full year, anticipating TECELRA sales of $35 million to $45 million. Adaptimmune reported invoicing 14 TECELRA treatments in 2025, including 6 in Q1, resulting in $4 million in net sales, and 8 additional invoiced treatments early in Q2. The company achieved 100% manufacturing success, with an average turnaround from apheresis to lot release of 27 days, surpassing the 30-day target. Adaptimmune's network includes 28 active treatment centers, with expectations to reach 30 by year-end, a year ahead of schedule. No patient access issues have been reported, with no denials to date. Adaptimmune foresees peak sales of $400 million from its TECELRA and lete-cel sarcoma franchise, with lete-cel launch activities underway, targeting a 2026 approval.

Adaptimmune Therapeutics Risk Analysis

Adaptimmune Therapeutics disclosed 82 risk factors in its most recent earnings report. Adaptimmune Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Although our financial statements have been prepared on a going concern basis, if we fail to obtain additional financing in the future, this may raise substantial doubt about our ability to continue as a going concern in future reporting periodsQ3, 2024
2.Tecelra is approved under accelerated approval in the United States, and additional confirmatory work is required in order to maintain that approval. Inability to maintain approval or to otherwise meet the requirements imposed by the FDA will have a significant impact on our ability to commercialize Tecelra.Q3, 2024
3.As part of the approval of Tecelra, certain post approval requirements apply which, if not satisfied, could impact continued approval of Tecelra.Q3, 2024

Adaptimmune Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:473A against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SNTISNTI42Neutral$4.38M-0.09-1539.97%――80.28%
BCABBCAB41Neutral$3.05M-0.0789.25%―-22.73%53.53%
XLOXLO41Neutral$56.13M-33.88-18.51%―72.97%97.20%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:473ABCABSNTIXLODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:473A and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:473AAdaptimmune Therapeutics Plc.0.01-0.02-58.62%
BCABBioatla, Inc.1.85-31.13-94.39%
SNTISenti Biosciences, Inc.0.16-1.63-91.23%
XLOXilio Therapeutics Inc8.47-1.35-13.76%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.